Across 56,754 adults with type 2 diabetes in Teladoc's remote monitoring program (2021-2025), estimated A1c from cellular glucose meters fell 0.06 percentage points per year, and the odds of reaching eA1c below 7% rose 8% annually, with predicted control climbing from 75.2% to 80.1%. Decomposition credited cardiorenal-protective antihyperglycemics (the drug classes now recommended first-line, such as SGLT2 inhibitors and GLP-1 agonists) with most of the explained trend change, while program engagement pulled in the opposite direction.
The headline is modest: 0.06 points per year is clinically small, and the 170.8% attribution figure is a statistical accounting artifact of Gelbach decomposition, not proof that drugs caused the improvement. The opposing engagement effect likely reflects survivorship and selection, since members who disengage may differ systematically from those who stay. Estimated A1c derived from fasting glucose is also an imperfect proxy for laboratory HbA1c, and there is no control group, so secular drug-prescribing trends and the program itself cannot be separated. Participants who keep meter-testing for years are probably motivated outliers, which flatters long-term durability. Still, the data fit what trials show: newer drug classes improve control and carry cardiorenal benefits beyond glucose. Practically, adults with type 2 diabetes should ask their clinician whether these agents suit them, since digital monitoring alone appears to add little on top. This is a preprint, not yet peer reviewed, so findings may shift. Editorially, it is confirmatory and incremental.